Claims
- 1. A compound of formula (I), ##STR28## a pharmaceutically acceptable acid or base addition salt thereof or a stereochemically isomeric form thereof, wherein
- A and B taken together form a bivalent radical of formula:
- --N.dbd.CH-- (a),
- --CH.dbd.N-- (b),
- --CH.sub.2 --CH.sub.2 -- (c),
- --CH.dbd.CH-- (d),
- --C(.dbd.O)--CH.sub.2 -- (e),
- --CH.sub.2 --C(.dbd.O)-- (f),
- wherein one hydrogen atom in the radicals (a) and (b) may be replaced with a C.sub.1-6 -alkyl-radical and up to two hydrogen atoms in radical (c), (d), (e) or (f) may be replaced by a C.sub.1-6 -alkyl-radical;
- D is a radical of formula ##STR29## L is a radical of formula ##STR30## Alk is a C.sub.1-4 alkanediyl radical; R.sup.1 is halo;
- R.sup.2 is hydrogen or halo;
- R.sup.3 is hydrogen, C.sub.1-6 alkyl, phenyl or halophenyl;
- R.sup.4 is hydrogen, C.sub.1-6 alkyl, phenyl or halophenyl;
- R.sup.5 is hydrogen or C.sub.1-6 alkyl;
- R.sup.6 is hydrogen, C.sub.1-6 alkyl, C.sub.1-6 alkyloxycarbonyl, or
- R.sup.5 and R.sup.6 taken together with the nitrogen atom to which they are attached form a pyrrolidine, piperidine, morpholine, piperazine or substituted piperazine ring, said substituted piperazine being a piperazine ring substituted on the 4-position of the piperazine ring with C.sub.1-6 alkyl, hydroxyC.sub.1-6 alkyl, aminoC.sub.1-6 alkyl, mono- or di(C.sub.1-6 alkyl) aminoC.sub.1-6 alkyl.
- 2. A compound according to claim 1, wherein D is a radical of formula (D.sub.1) or (D.sub.2).
- 3. A compound according to claim 2, wherein D is a radical of formula (D.sub.1), wherein R.sup.1 is chloro or fluoro and R.sup.2 is hydrogen, chloro or fluoro; L is a radical of formula (L.sub.1), wherein R.sup.3 and R.sup.4 each independently are phenyl or hydrogen.
- 4. A compound according to claim 3, wherein the compound is (.+-.)-cis-4-�4-�4-�4-��2-(2,4-difluorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl!methoxy!phenyl!-1-piperazinyl!phenyl!-2-�3,3-dimethyl-2-(phosphonooxy)butyl!-2,4-dihydro-3H-1,2,4-triazol-3-one, a stereochemically isomeric form or a base addition salt form thereof.
- 5. A composition comprising a pharmaceutically acceptable carrier and as active ingredient an antifungally effective amount of a compound as claimed in claim 1.
- 6. A composition comprising a pharmaceutically acceptable carrier and as active ingredient an antifungally effective amount of a compound as claimed in claim 2.
- 7. A composition comprising a pharmaceutically acceptable carrier and as active ingredient an antifungally effective amount of a compound as claimed in claim 3.
- 8. A composition comprising a pharmaceutically acceptable carrier and as active ingredient an antifungally effective amount of a compound as claimed in claim 4.
- 9. A method of inhibiting the development of or eliminating fungi in warm blooded animals suffering from infection by said fungi, which method comprises administering to said warm blooded animals an antifungally effective amount of a compound as claimed in claim 1.
- 10. A method of inhibiting the development of or eliminating fungi in warm blooded animals suffering from infection by said fungi, which method comprises administering to said warm blooded animals an antifungally effective amount of a compound as claimed in claim 2.
- 11. A method of inhibiting the development of or eliminating fungi in warm blooded animals suffering from infection by said fungi, which method comprises administering to said warm blooded animals an antifungally effective amount of a compound as claimed in claim 3.
- 12. A method of inhibiting the development of or eliminating fungi in warm blooded animals suffering from infection by said fungi, which method comprises administering to said warm blooded animals an antifungally effective amount of a compound as claimed in claim 4.
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is based upon PCT Application Ser. No. PCT/EP 95/00174, filed Jan. 17, 1995, which is a continuation-in-part of U.S. patent application Ser. No. 08/185,352, filed on Jan. 24, 1994, now abandoned.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
102e Date |
371c Date |
PCT/EP95/00174 |
1/17/1995 |
|
|
6/20/1996 |
6/20/1996 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO95/19983 |
7/27/1995 |
|
|
US Referenced Citations (3)
Number |
Name |
Date |
Kind |
4267179 |
Heeres et al. |
May 1981 |
|
4791111 |
Heeres et al. |
Dec 1988 |
|
5039676 |
Saksena et al. |
Aug 1991 |
|
Foreign Referenced Citations (4)
Number |
Date |
Country |
228125 |
Jul 1987 |
EPX |
283992 |
Sep 1988 |
EPX |
539938 |
May 1993 |
EPX |
9517407 |
Jun 1995 |
WOX |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
185352 |
Jan 1994 |
|